bpc_157 BPC-157 – No Proof Required! | Office for Science and Society BPC-157 – Research Peptide |

The maximum approved dose produces the greatest weight loss in clinical trials but also the highest side effect incidence

Rodrigues, M., Ezzedine, K

NAD+ Specifications Product name: NAD+ (Nicotinamide Adenine Dinucleotide, oxidised) Synonyms: Coenzyme I

This reduces risk and improves the likelihood of positive outcomes

Originally developed as a treatment for Type 2 diabetes, Semaglutide has been FDA-approved for weight loss in individuals with obesity

While more human data is needed, its mechanism aligns with many principles of functional and longevity medicine namely, supporting mitochondria, reducing inflammation, and improving insulin sensitivity